MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA ATTENUATES PLASMA INTERLEUKIN-6 LEVELS IN PORCINE GRAM-NEGATIVE SEPSIS

Citation
Pg. Mullen et al., MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA ATTENUATES PLASMA INTERLEUKIN-6 LEVELS IN PORCINE GRAM-NEGATIVE SEPSIS, The Journal of surgical research, 57(5), 1994, pp. 625-631
Citations number
42
Categorie Soggetti
Surgery
ISSN journal
00224804
Volume
57
Issue
5
Year of publication
1994
Pages
625 - 631
Database
ISI
SICI code
0022-4804(1994)57:5<625:MTTAPI>2.0.ZU;2-Q
Abstract
This study examined the kinetics of IL-6 release into the systemic cir culation in a porcine model of bacterial sepsis induced by infusion of live Pseudomonas aeruginosa. Three groups of animals were studied. Gr oup I (n = 12) animals received a 1 hr infusion of live P. aeruginosa. Group II (n = 6) animals received monoclonal antibody to tumor necros is factor-alpha (TNP-alpha) (15 mg/kg) prior to induction of sepsis. G roup III (n = 7) animals received sterile saline only. TNF-alpha and i nterleukin-6 (IL-6) levels rose sharply, in group I following pseudomo nas infusion. Following a peak at 120 min after the bacterial infusion (4.8 +/- 0.7 U/ml at 120 min vs 0.4 +/- 0.2 U/ml at 0 min), TNF-alpha levels subsequently declined prior to the end of the experiment. In c ontrast, IL-6 levels rose sharply, subsequent to TNF-alpha, peaked at 180 min, and remained significantly elevated throughout the study peri od (5.3 +/- 0.9 ng/ml vs 0.05 +/- 0.01 ng/ml, 0 min). In animals pretr eated with monoclonal antibody to TNF-alpha, no increase in TNF-alpha activity was detected at any time during the period of study. IL-6 lev els in antibody-treated animals, although greatly attenuated, still ro se significantly above baseline (2.02 +/- 0.8 ng/ml at 180 min vs 0.05 +/- 0.01 ng/ml at 0 min) and above levels in control animals. We conc lude that although TNF-alpha plays an important role in synthesis and release of IL-6, there is a TNF-alpha-independent pathway for release of IL-6 in sepsis. (C) 1994 Academic Press, Inc.